Skip to main content

Copper

Copper is an essential trace element that serves as a cofactor for approximately 25 cuproenzymes critical to oxidative metabolism, antioxidant defense, neurotransmitter synthesis, connective tissue formation, iron metabolism, and immune function.[1][2][3] The adult body contains approximately 75–100 mg of copper, with the liver as the primary storage organ.[4] Copper occupies a unique position in medicine as the element central to two well-characterized genetic diseases with diametrically opposite pathophysiology: Menkes disease (deficiency) and Wilson disease (toxicity).[5][6]

For the reconstructive urologist and urogynecologist, copper carries one defining urologic presentation and four secondary reconstructive scenarios. The defining presentation: a patient on long-term zinc supplements or denture-adhesive cream walks into clinic with progressive paresthesias, gait instability, sensory ataxia, and a new neurogenic-bladder pattern that mimics B12-related subacute combined degeneration — but the B12 is normal. This is copper-deficiency myeloneuropathy, and it is the urology-relevant zinc-page mirror image. The other four: post-bariatric reconstruction, TPN-dependent patients, the MDS-misdiagnosis trap in post-bariatric anemia + neutropenia, and Wilson disease patients on chelation / zinc maintenance facing reconstruction.

Biochemistry and Homeostasis​

Dietary copper is absorbed primarily in the duodenum and proximal jejunum via the copper transporter CTR1 (SLC31A1), which imports reduced Cu⁺ into enterocytes.[4] From enterocytes, copper is exported into the portal circulation by the copper-transporting ATPase ATP7A and travels to the liver bound to albumin and histidine. Within hepatocytes, copper is incorporated into ceruloplasmin (which carries ~ 90% of circulating copper), delivered to cuproenzymes, or excreted into bile via ATP7B — the primary route of elimination.[4]

Key Copper-Dependent Enzymes​

EnzymeFunctionClinical Relevance of Deficiency
Cytochrome c oxidaseTerminal electron-transport-chain enzyme; mitochondrial respirationMitochondrial dysfunction, lactic acidosis
Cu/Zn superoxide dismutase (SOD1)Antioxidant defense; scavenges superoxide radicalsOxidative stress; SOD1 mutations → ALS
Ceruloplasmin (ferroxidase)Iron oxidation (Fe²⁺ → Fe³⁺) for transferrin loadingIron-refractory anemia; aceruloplasminemia
Lysyl oxidaseCrosslinks collagen and elastin in connective tissueVascular fragility, bone abnormalities, skin laxity
Dopamine-β-hydroxylaseConverts dopamine → norepinephrineDysautonomia, orthostatic hypotension (Menkes)
TyrosinaseMelanin synthesisHypopigmentation of hair and skin
Peptidylglycine α-amidating monooxygenase (PAM)Amidation of neuropeptidesImpaired neuropeptide signaling

Dietary Sources and Requirements​

Copper is found in organ meats (especially liver), shellfish, nuts, seeds, chocolate, legumes, and whole grains.[4] The RDA for healthy adults is 0.9 mg/day; median US dietary intake (1–1.6 mg/day) generally meets requirements.[7][4] The UL is 10 mg/day.[8] In parenteral nutrition, the recommended copper provision is 0.3 mg/day IV.[7]

Assessment of Copper Status​

  • Serum copper — Normal ~ 80–155 μg/dL. Total serum copper reflects both ceruloplasmin-bound (~ 90%) and free copper. Low levels suggest deficiency; markedly elevated levels with low ceruloplasmin suggest Wilson disease with acute liver injury.[4][9]
  • Serum ceruloplasmin — Normal ~ 20–40 mg/dL. Low in copper deficiency, Wilson disease, severe liver disease, protein-losing states, Menkes. Ceruloplasmin is an acute-phase reactant — elevated by inflammation, estrogen, and pregnancy, which can mask deficiency.[4]
  • 24-hour urinary copper — Elevated (> 40 μg/day, typically > 100 μg/day) in Wilson disease; low in copper deficiency.[10][11]
  • Non-ceruloplasmin-bound copper (NCC) — Calculated as total serum copper minus (3.15 × ceruloplasmin in mg/dL). Normal 10–15 μg/dL; elevated > 25 μg/dL in untreated Wilson disease.[4]
  • Erythrocyte SOD activity and platelet cytochrome c oxidase — More sensitive functional markers for marginal deficiency, but not widely available clinically.[1]

Causes of Deficiency​

CategoryExamples
Zinc-inducedExcessive zinc supplements, zinc-containing denture adhesives, coin ingestion
MalabsorptionBariatric surgery (RYGB, BPD/DS), celiac disease, short bowel syndrome, IBD
Inadequate intakeTPN without copper supplementation, severe malnutrition
Increased lossesProlonged continuous renal-replacement therapy
GeneticMenkes disease (ATP7A mutations)

Zinc-induced copper deficiency deserves particular emphasis. Excess zinc upregulates metallothionein in enterocytes, which has a higher affinity for copper than zinc. When these enterocytes are sloughed, copper is lost into the GI tract — a functional copper malabsorption state.[12] A 2026 systematic review of 37 cases found zinc-induced hematologic toxicity most commonly resulted from oral supplements, denture-adhesive creams, and coin ingestion, with daily elemental zinc doses ranging from ~ 50 mg to > 1,500 mg.[13] In a Scottish national review, 9 of 16 copper-deficient patients were using zinc-containing dental fixatives at diagnosis.[12] A study of 70 patients prescribed zinc found 62% received doses sufficient to cause copper deficiency, yet copper status was measured in only 2 patients — 9% developed unexplained anemia and 7% developed neurological symptoms typical of copper deficiency.[14]

Clinical Manifestations of Deficiency​

Hematologic — The MDS Mimic​

The most common and earliest manifestation. Copper deficiency causes anemia (macrocytic, normocytic, or microcytic), neutropenia, and less commonly thrombocytopenia or pancytopenia.[7][12][15] Bone marrow findings include vacuolated myeloid and erythroid precursors, ring sideroblasts, and multilineage dysplasia — frequently leading to misdiagnosis as myelodysplastic syndrome (MDS).[12][13] In the Scottish national review, 94% of patients had hematologic features as the initial manifestation, with bone marrow appearances mimicking refractory cytopenia with multilineage dysplasia or MDS.[12] Critically, 93% of cytopenias resolved with copper replacement — check copper before diagnosing MDS in any post-bariatric or zinc-using patient.[12]

Neurologic — Myeloneuropathy Mimicking B12 SCD​

Myeloneuropathy mimicking subacute combined degeneration (vitamin B12 deficiency) is the most important neurologic manifestation, peaking in the 5th–6th decades with a female predominance.[16][9] Patients present with:

  • Posterior column dysfunction (sensory ataxia, loss of vibration / proprioception)
  • Spasticity and hyperreflexia (UMN signs)
  • Peripheral neuropathy (large fiber > small fiber)
  • New neurogenic-bladder pattern (urgency, retention, incomplete emptying) — the urologic presentation

MRI characteristically shows a T2 hyperintense "inverted V" signal in the dorsal columns of the cervical or thoracic cord — identical to the pattern seen in B12 deficiency.[9] A systematic review of 198 cases of copper deficiency myelopathy found the most common etiology was prior gastric surgery (36.2%), followed by excessive zinc consumption from denture cream (19.9%). Mean serum copper was profoundly low at 15.67 μg/dL. Only 24% showed neurological improvement with supplementation, and only 5.1% recovered to baseline — emphasizing that neurological damage is often irreversible and early detection is critical.[9]

Other​

Hypopigmentation of hair, impaired wound healing, osteoporosis, increased susceptibility to infections (neutropenia + impaired phagocytic function).[1][8][17]

Immune Function​

Copper is essential for both innate and adaptive immunity. Neutropenia is a hallmark of deficiency, and even marginal deficiency impairs neutrophil and macrophage phagocytosis, oxidative burst, and microbial killing.[17] Macrophages actively accumulate copper in phagosomes via ATP7A translocation to kill intracellular pathogens — a mechanism particularly important in defense against mycobacteria.[18][19]

Treatment of Copper Deficiency​

No standardized guidelines exist, but the following approach is generally recommended:[7][16][20]

  • Severe deficiency (neurologic or severe hematologic) — IV copper 2–4 mg/day for 6 days, followed by oral copper 3–8 mg/day until levels normalize.
  • Mild-to-moderate deficiency — Oral copper sulfate or gluconate 2–4 mg/day elemental copper.
  • Maintenance / prophylaxis — 2 mg/day as part of a routine multivitamin-mineral.
  • When supplementing zinc — Add 1 mg copper for every 8–15 mg elemental zinc to prevent zinc-induced depletion.[20]

Hematologic manifestations typically resolve within 4–12 weeks of supplementation; neurological recovery is incomplete in the majority of cases.[12][15][9]

Post-Bariatric Surgery Monitoring​

The AACE/TOS/ASMBS 2019 guidelines recommend:[20]

  • Routine copper supplementation (2 mg/day) in all post-bariatric patients.
  • Annual screening with serum copper + ceruloplasmin for all RYGB and BPD/DS patients.
  • Screening in any post-bariatric patient with anemia, neutropenia, myeloneuropathy, or impaired wound healing.
  • At 5 years post-RYGB, 13.5% of patients had low copper levels.

Genetic Disorders of Copper Metabolism​

Menkes Disease​

X-linked recessive disorder caused by mutations in ATP7A, resulting in impaired intestinal copper absorption and defective copper delivery to cuproenzymes.[11][21] Clinical features reflect decreased activity of copper-dependent enzymes:

  • Presents at 2–3 months of age with hypotonia, seizures, failure to thrive, progressive neurodegeneration.
  • Characteristic sparse, kinky ("steely") hair, hypopigmentation, connective-tissue abnormalities.
  • Low serum copper and ceruloplasmin (though unreliable in neonates).
  • Without treatment, death typically by age 3 years.

Treatment with subcutaneous copper histidinate can prevent neurodegeneration if initiated within days of birth, but outcomes depend on the specific ATP7A mutation and timing.[21][22] Survivors often develop dysautonomia from persistent dopamine-β-hydroxylase deficiency; a 2026 phase 1/2a trial demonstrated that droxidopa can bypass this enzymatic defect and improve orthostatic hypotension.[23]

Wilson Disease​

Autosomal recessive disorder caused by mutations in ATP7B, resulting in impaired biliary copper excretion and toxic copper accumulation in liver, brain, cornea, kidneys.[4][6][10] Key features:

  • Progressive liver disease (hepatitis, cirrhosis, acute liver failure).
  • Neuropsychiatric manifestations (dystonia, tremor, dysarthria, psychiatric symptoms).
  • Kayser-Fleischer rings (corneal copper deposition in Descemet's membrane).
  • Low ceruloplasmin (< 20 mg/dL), elevated 24-hour urine copper (> 100 μg/day), elevated hepatic copper on biopsy.[10][4]

AASLD 2022 Practice Guidance recommends chelation therapy (D-penicillamine or trientine) for symptomatic patients and zinc (150 mg elemental zinc/day in divided doses) for asymptomatic patients or as maintenance therapy.[4] Zinc works by inducing enterocyte metallothionein to block copper absorption.

Cuproptosis — An Emerging Concept​

Cuproptosis (2022) is a recently described form of copper-dependent regulated cell death distinct from apoptosis, necrosis, and ferroptosis.[24][25] Excess intracellular copper directly binds to lipoylated proteins in the TCA cycle (particularly DLAT), causing aggregation and destabilizing iron-sulfur cluster proteins → mitochondrial proteotoxic stress and cell death.[24][26] Particularly active in cells relying on oxidative phosphorylation — a potential therapeutic vulnerability in certain cancers, currently preclinical.[25]

Reconstructive Relevance​

1. The Defining Urologic Presentation — Copper-Deficiency Myeloneuropathy with New Neurogenic Bladder​

This is the most clinically distinctive copper presentation in urology. The classic patient:

  • Adult (5th–6th decade), often female (per Chen 2024 systematic review of 198 cases).
  • Long history of zinc supplementation (self-prescribed for cold prevention, AMD per AREDS, "immune support") OR chronic denture-adhesive cream use (older edentulous patients) OR distant gastric / bariatric surgery (36.2% of cases).
  • Presents with progressive sensory ataxia, gait instability, paresthesias, and a NEW neurogenic-bladder pattern (urgency, retention, incomplete emptying).
  • B12 and MMA are normal — the differential reflexively lands on B12, and copper gets missed.

Workup: serum copper, ceruloplasmin, zinc, and B12. MRI shows the same "inverted V" T2 dorsal-column signal as B12 SCD.

Treatment: remove the zinc source (stop oral zinc; switch denture creams; remove ingested coin if applicable) AND replete copper (IV 2–4 mg/day × 6 days for severe disease, then oral 3–8 mg/day; or oral 2–4 mg/day for mild-to-moderate).

Prognosis: hematologic abnormalities resolve in 93%, but only 24% show neurological improvement and only 5.1% recover to baseline. Early detection is critical and often missed. Always ask about zinc supplements and denture cream in any patient presenting with myeloneuropathy + new neurogenic bladder when B12 is normal.

Cross-reference: Zinc and Vitamin B12.

2. Post-Bariatric Reconstruction Surveillance​

Copper deficiency at 5 years post-RYGB affects 13.5% of patients, and the proportion rises further with BPD/DS. For any post-bariatric patient presenting for elective reconstruction:

  • Verify ASMBS supplementation status (2 mg/day copper as part of bariatric multivitamin).
  • Check baseline serum copper + ceruloplasmin before major reconstruction.
  • Annual surveillance indefinitely after RYGB / BPD/DS per ASMBS 2019.

3. The MDS-Misdiagnosis Trap — Post-Bariatric Anemia + Neutropenia​

A post-bariatric patient presenting with anemia + neutropenia ± thrombocytopenia frequently triggers hematology referral for suspected MDS — particularly because bone marrow shows vacuolated precursors, ring sideroblasts, and multilineage dysplasia, identical to MDS morphology. 93% of cytopenias resolve with copper replacement.

Always check serum copper + ceruloplasmin before MDS workup in any post-bariatric patient (or chronic zinc / denture-cream user) presenting with cytopenias. This is one of the highest-yield "rescue" diagnoses in the cross-section between nutritional medicine and hematology.

4. TPN-Dependent Patients Facing Reconstruction​

Patients on long-term home TPN for short-bowel syndrome, enterocutaneous fistula, or radiation enteritis facing reconstruction (fistula repair, bowel reconstruction, complex pelvic surgery) require 0.3 mg copper/day IV as standard trace-element supplementation per ASPEN. Verify in TPN orders before any major reconstruction. Patients on prolonged CRRT also lose copper urinarily.

5. Wilson Disease Patients Facing Reconstruction​

Wilson disease patients on maintenance zinc therapy (150 mg/day) or chelation (penicillamine, trientine) require:

  • Continuation of treatment throughout the perioperative period (interruption can precipitate copper rebound and acute liver injury).
  • Coordination with hepatology for any major elective reconstruction.
  • Separation of zinc and chelator by ≥ 4–5 hours if both are used.
  • Special caution with D-penicillamine — interferes with wound healing (chelates copper from lysyl oxidase, impairing collagen crosslinking); the surgical team may request a brief preoperative switch to trientine when feasible.

See Also​

References​

1. Olivares M, Uauy R. "Copper as an Essential Nutrient." The American Journal of Clinical Nutrition. 1996;63(5):791S–796S. doi:10.1093/ajcn/63.5.791

2. Maung MT, Carlson A, Olea-Flores M, et al. "The Molecular and Cellular Basis of Copper Dysregulation and Its Relationship With Human Pathologies." FASEB Journal. 2021;35(9):e21810. doi:10.1096/fj.202100273RR

3. Gale J, Aizenman E. "The Physiological and Pathophysiological Roles of Copper in the Nervous System." European Journal of Neuroscience. 2024;60(1):3505–3543. doi:10.1111/ejn.16370

4. Schilsky ML, Roberts EA, Bronstein JM, et al. "A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 AASLD Practice Guidance." Hepatology. 2022. doi:10.1002/hep.32801

5. Horn N, Møller LB, Nurchi VM, Aaseth J. "Chelating Principles in Menkes and Wilson Diseases: Choosing the Right Compounds in the Right Combinations at the Right Time." Journal of Inorganic Biochemistry. 2019;190:98–112. doi:10.1016/j.jinorgbio.2018.10.009

6. Członkowska A, Litwin T, Dusek P, et al. "Wilson Disease." Nature Reviews Disease Primers. 2018;4(1):21. doi:10.1038/s41572-018-0018-3

7. Altarelli M, Ben-Hamouda N, Schneider A, Berger MM. "Copper Deficiency: Causes, Manifestations, and Treatment." Nutrition in Clinical Practice. 2019;34(4):504–513. doi:10.1002/ncp.10328

8. Uauy R, Olivares M, Gonzalez M. "Essentiality of Copper in Humans." The American Journal of Clinical Nutrition. 1998;67(5 Suppl):952S–959S. doi:10.1093/ajcn/67.5.952S

9. Chen JW, Zeoli T, Hughes NC, Lane A, Berkman RA. "Copper Deficiency Myelopathy Mimicking Cervical Spondylitic Myelopathy: A Systematic Review of the Literature With Case Report." The Spine Journal. 2024;24(11):2026–2034. doi:10.1016/j.spinee.2024.06.018

10. Roberts EA, Schilsky ML. "Current and Emerging Issues in Wilson's Disease." The New England Journal of Medicine. 2023;389(10):922–938. doi:10.1056/NEJMra1903585

11. Bandmann O, Weiss KH, Kaler SG. "Wilson's Disease and Other Neurological Copper Disorders." The Lancet Neurology. 2015;14(1):103–113. doi:10.1016/S1474-4422(14)70190-5

12. Gabreyes AA, Abbasi HN, Forbes KP, et al. "Hypocupremia associated cytopenia and myelopathy: a national retrospective review." European Journal of Haematology. 2013;90(1):1–9. doi:10.1111/ejh.12020

13. Dutta A, Chaudhary V, Kumari S, et al. "Zinc-Induced Hematologic Toxicities: A Systematic Review of Descriptive Studies." Biological Trace Element Research. 2026. doi:10.1007/s12011-026-05136-z

14. Duncan A, Yacoubian C, Watson N, Morrison I. "The Risk of Copper Deficiency in Patients Prescribed Zinc Supplements." Journal of Clinical Pathology. 2015;68(9):723–725. doi:10.1136/jclinpath-2014-202837

15. Myint ZW, Oo TH, Thein KZ, Tun AM, Saeed H. "Copper Deficiency Anemia: Review Article." Annals of Hematology. 2018;97(9):1527–1534. doi:10.1007/s00277-018-3407-5

16. Gwathmey KG, Grogan J. "Nutritional neuropathies." Muscle & Nerve. 2020;62(1):13–29. doi:10.1002/mus.26783

17. Stefanache A, Lungu II, Butnariu IA, et al. "Understanding How Minerals Contribute to Optimal Immune Function." Journal of Immunology Research. 2023;2023:3355733. doi:10.1155/2023/3355733

18. Neyrolles O, Wolschendorf F, Mitra A, Niederweis M. "Mycobacteria, metals, and the macrophage." Immunological Reviews. 2015;264(1):249–263. doi:10.1111/imr.12265

19. Focarelli F, Giachino A, Waldron KJ. "Copper Microenvironments in the Human Body Define Patterns of Copper Adaptation in Pathogenic Bacteria." PLoS Pathogens. 2022;18(7):e1010617. doi:10.1371/journal.ppat.1010617

20. Mechanick JI, Apovian C, Brethauer S, et al. "Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures — 2019 Update." Obesity. 2020;28(4):O1–O58. doi:10.1002/oby.22719

21. Kaler SG, Holmes CS, Goldstein DS, et al. "Neonatal Diagnosis and Treatment of Menkes Disease." The New England Journal of Medicine. 2008;358(6):605–614. doi:10.1056/NEJMoa070613

22. Kaler SG. "Neurodevelopment and Brain Growth in Classic Menkes Disease Is Influenced by Age and Symptomatology at Initiation of Copper Treatment." Journal of Trace Elements in Medicine and Biology. 2014;28(4):427–430. doi:10.1016/j.jtemb.2014.08.008

23. Kaler MM, Brock G, Jeanty CJ, et al. "Safety and Efficacy of Droxidopa for Dysautonomia in Adults With Menkes Disease and Occipital Horn Syndrome in the USA: A Randomised Phase 1/2a Crossover Trial." EClinicalMedicine. 2026;94:103898. doi:10.1016/j.eclinm.2026.103898

24. Liu WQ, Lin WR, Yan L, Xu WH, Yang J. "Copper homeostasis and cuproptosis in cancer immunity and therapy." Immunological Reviews. 2024;321(1):211–227. doi:10.1111/imr.13276

25. Qin W, Sheng H, Hu X, et al. "Cuproptosis in Cancer: Emerging Mechanism and Therapeutic Opportunities." Trends in Pharmacological Sciences. 2026;47(4):386–402. doi:10.1016/j.tips.2026.02.004

26. Liu S, Chang Y, Li J, et al. "Copper and Cuproptosis: From Homeostasis to Pathogenesis." Chemico-Biological Interactions. 2026;431:112007. doi:10.1016/j.cbi.2026.112007